Crinetics Pharmaceuticals, Inc.
CRNX
$83.65
-0.08%
Crinetics Pharmaceuticals is a commercial-stage biotechnology company focused on discovering, developing, and commercializing novel therapies for rare endocrine diseases and endocrine-related tumors. Its lead product, Palsonify (paltusotine), is an FDA-approved once-daily oral treatment for acromegaly, positioning the company as a niche player in the rare endocrine space with a commercial foothold. The stock is currently at the center of a transformative event: Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics at a 102% premium, driving the stock to near its 52-week high and sparking debate about whether the deal fully captures the long-term value of the pipeline, including late-stage candidate atumelnant for congenital adrenal hyperplasia.…
CRNX
Crinetics Pharmaceuticals, Inc.
$83.65
Related headlines
Investment Opinion: Should I buy CRNX Today?
Rating: Hold. The stock is fairly valued near the acquisition price, offering limited upside but also downside protection if the deal closes. The consensus analyst rating is 'hold' with an average target of $82.50, implying -1.6% downside from the current price of $83.86.
Supporting Evidence: The trailing PS ratio of 568.9x is extreme but justified by the acquisition premium; forward PS of ~2.8x based on estimated revenue of $1.56 billion is reasonable. Revenue grew 28.7% YoY in Q1 2026, and gross margin is 98.1%. However, the company is unprofitable with negative EPS and free cash flow. The analyst high target of $90 offers only 7.3% upside, while the low target of $55 implies -34.4% downside, reflecting the binary risk.
Risks & Conditions: The biggest risk is deal failure, which would invalidate the Hold thesis and likely trigger a Sell. If the deal closes, the stock should trade near the offer price, offering minimal upside. This Hold would upgrade to Buy if the stock dips significantly below the offer price (e.g., below $75) on deal uncertainty, or downgrade to Sell if regulatory hurdles emerge. Valuation verdict: The stock is fairly valued relative to the acquisition price but overvalued on a standalone basis.
Sign up to view all
CRNX 12-Month Price Forecast
The 12-month outlook for CRNX is dominated by the Vertex acquisition. The base case (60% probability) sees the stock trading near the offer price with limited upside. The bull case (20%) requires successful deal closure and pipeline upside, while the bear case (20%) involves deal failure and a sharp decline. The neutral stance reflects the balanced risk/reward: the stock is fairly priced if the deal closes, but the downside risk is severe if it fails. Upgrading to bullish would require a significant discount to the offer price or clear regulatory approval; downgrading to bearish would require signs of deal collapse.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Crinetics Pharmaceuticals, Inc.'s 12-month outlook, with a consensus price target around $82.50 and implied upside of -1.4% versus the current price.
Average Target
$82.50
0 analysts
Implied Upside
-1.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$55 - $90
Analyst target range
The stock is covered by 10 analysts, with a consensus recommendation of 'hold' and an average target price of $82.50. The current price of $83.86 is slightly above the average target, implying a -1.6% downside to the consensus. The distribution shows a notable shift: on July 7-8, 2026, multiple analysts downgraded the stock from Buy to Hold/Neutral following the acquisition announcement, reflecting the limited upside at the offer price. The target range spans from $55.00 (low) to $90.00 (high). The high target of $90.00 assumes the deal closes successfully and the pipeline delivers additional value, while the low target of $55.00 may reflect skepticism about the deal's completion or dilution risks. The wide spread ($35.00) indicates high uncertainty, but the recent downgrades suggest analysts see limited upside from current levels near the offer price.
Bulls vs Bears: CRNX Investment Factors
Crinetics is a binary event stock, with its value almost entirely determined by the Vertex acquisition. The bull case rests on the deal closing and the pipeline's long-term potential, while the bear case centers on limited upside from current levels and the risk of deal failure. Currently, the bull case has stronger evidence given the signed agreement and premium, but the stock offers minimal upside to the offer price. The single most important tension is whether the acquisition will close as announced; if it does, the stock is fairly valued near $83.86, but if it fails, a catastrophic decline to the $25-$55 range is possible.
Bullish
- Vertex Acquisition at 102% Premium: Vertex Pharmaceuticals is acquiring Crinetics for $10 billion, a 102% premium to the pre-announcement price. This validates the value of Palsonify and the pipeline, providing a clear floor near $83.86.
- Strong Revenue Growth Trajectory: Q1 2026 revenue grew 28.7% YoY to $10.7 million, driven by Palsonify launch. Analysts project full-year revenue of $1.56 billion, implying massive scale-up post-acquisition.
- High Gross Margin Business: Gross margin is 98.1% in Q1 2026, typical for a proprietary drug. This indicates strong pricing power and scalability once fixed costs are covered.
- Solid Balance Sheet with Low Debt: Debt-to-equity ratio is only 0.049 and current ratio is 12.3, providing ample liquidity to fund operations and pipeline development without distress.
Bearish
- Limited Upside from Current Price: Current price of $83.86 is above the average analyst target of $82.50, implying -1.6% downside. The high target of $90 offers only 7.3% upside, capping near-term returns.
- Negative Earnings and Cash Burn: EPS is -$1.23 and free cash flow is -$125.5 million in Q1 2026. The company is unprofitable and relies on equity issuance ($389.9 million in Q1) to fund operations.
- Acquisition Completion Risk: The deal may face regulatory hurdles or shareholder opposition. If it fails, the stock could collapse back to the 52-week low of $25.83, a -69% decline.
- Low Beta May Mislead Risk: Beta of 0.23 suggests low volatility, but the stock's 1-month change of +134.6% shows extreme event-driven risk. The low beta is historical and not reflective of current binary outcome.
CRNX Technical Analysis
The stock is in a powerful uptrend, with a 1-year price change of +154.0%, massively outperforming the S&P 500's +18.4%. The current price of $83.86 sits at 99.8% of its 52-week range (low $25.83, high $84.00), indicating the stock is trading near its all-time highs, reflecting strong momentum and bullish sentiment following the acquisition announcement. The 1-month price change is +134.6%, while the 3-month change is +104.5%, showing accelerating short-term momentum that far exceeds the longer-term trend, driven by the Vertex acquisition news on July 7, 2026. The 1-month relative strength versus the S&P 500 is +134.3%, confirming the stock is in a powerful breakout phase. The 52-week low of $25.83 and high of $84.00 define key support and resistance levels. A breakout above $84.00 would signal a continuation of the uptrend, while a breakdown below $55.00 (the low analyst target) could indicate a reversal. The stock's beta of 0.23 is surprisingly low, suggesting it is less volatile than the market, but this may be misleading given the recent price surge; the low beta likely reflects the stock's historical correlation rather than current behavior.
Beta
0.23
0.23x market volatility
Max Drawdown
-42.2%
Largest decline past year
52-Week Range
$26-$84
Price range past year
Annual Return
+170.0%
Cumulative gain past year
| Period | CRNX Return | S&P 500 |
|---|---|---|
| 1m | +132.9% | +0.6% |
| 3m | +118.2% | +3.4% |
| 6m | +57.3% | +7.1% |
| 1y | +170.0% | +16.4% |
| ytd | +79.0% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CRNX Fundamental Analysis
Revenue is growing rapidly, with Q1 2026 revenue of $10.7 million, up 28.7% year-over-year, driven by the launch of Palsonify. However, revenue remains modest, and the company is still in the early stages of commercialization. The company is not yet profitable, with a net loss of $127.8 million in Q1 2026 and an EPS of -$1.23. Gross margin is high at 98.1%, typical for a biotech with a proprietary drug, but operating margin is deeply negative at -67.1%, reflecting heavy R&D and SG&A spending. The balance sheet is solid, with a debt-to-equity ratio of just 0.049 and a current ratio of 12.3, indicating ample liquidity. However, free cash flow is negative at -$125.5 million in Q1 2026, and the company relies on external financing (equity issuance of $389.9 million in Q1 2026) to fund operations. ROE is -46.9%, reflecting the net loss position.
Quarterly Revenue
$10734000.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
98.1%
Latest Quarter
Free Cash Flow
$-419516000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CRNX Overvalued?
Since net income is negative, the price-to-sales (PS) ratio is the most appropriate valuation metric. The trailing PS ratio is 568.9x, while the forward PS ratio (based on estimated revenue of $1.56 billion) is approximately 2.8x, implying the market expects massive revenue growth from the acquisition. The EV/Sales ratio is 420.8x on a trailing basis. Compared to the biotechnology industry average PS ratio (typically 5-10x for commercial-stage companies), Crinetics trades at a massive premium on trailing sales, but the forward PS is more reasonable given the acquisition premium. The stock's own historical PS ratio has ranged from 0x (pre-revenue) to over 27,000x, so the current trailing PS of 568.9x is elevated but not unprecedented for a biotech with a newly approved drug. The forward PS of ~2.8x suggests the market is pricing in the acquisition at a reasonable multiple of projected sales.
PE
-9.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-9.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Crinetics is not profitable, with a net loss of $127.8 million in Q1 2026 and negative free cash flow of $125.5 million. The company relies on external financing, having raised $389.9 million in equity in Q1 2026. While the balance sheet is strong (current ratio 12.3), continued cash burn without acquisition proceeds could strain liquidity. Revenue is still modest at $10.7 million per quarter, making the company dependent on Palsonify's commercial success and pipeline progress.
Market & Competitive Risks: The stock trades at a trailing PS ratio of 568.9x, far above the biotech industry average of 5-10x, reflecting the acquisition premium. If the deal fails, the stock would likely re-rate to a more reasonable multiple, potentially falling to the low analyst target of $55 or even the 52-week low of $25.83. The low beta of 0.23 understates the binary risk; the stock's 1-month surge of 134.6% shows extreme event sensitivity. Regulatory or antitrust issues could derail the Vertex deal, and competition in acromegaly or CAH could erode pipeline value.
Worst-Case Scenario: If the Vertex acquisition fails due to regulatory or shareholder issues, the stock could plummet to the 52-week low of $25.83, a -69% decline from the current price of $83.86. This scenario assumes a loss of confidence in standalone prospects, with the stock potentially falling below the low analyst target of $55. The historical max drawdown of -42.21% (from a previous high) provides a reference, but the binary nature of the deal makes a larger decline possible.
FAQ
The primary risk is acquisition failure: if the Vertex deal falls through due to regulatory or shareholder issues, the stock could drop to the 52-week low of $25.83 (-69%). Financial risks include negative earnings (EPS -$1.23) and cash burn (FCF -$125.5 million in Q1 2026), which would become critical if the deal fails. Market risks include the stock's extreme valuation (trailing PS 568.9x) and low beta (0.23) that understates event-driven volatility. Company-specific risks include dependence on Palsonify for revenue and pipeline setbacks for atumelnant. The most severe risk is deal failure, which would likely trigger a catastrophic decline.
The 12-month forecast is dominated by the Vertex acquisition. The base case (60% probability) expects the stock to trade near the offer price of $83.86, with a target range of $80-$84. The bull case (20% probability) sees the stock reaching $84-$90 if the deal closes and pipeline value is recognized. The bear case (20% probability) projects a decline to $25.83-$55 if the deal fails. The most likely scenario is the base case, assuming the acquisition closes without issues. The stock's price will largely track deal developments, with limited fundamental catalysts until the transaction is completed.
On a standalone basis, CRNX is extremely overvalued with a trailing PS ratio of 568.9x, far above the biotech industry average of 5-10x. However, this valuation is justified by the Vertex acquisition at a 102% premium. On a forward basis, using estimated revenue of $1.56 billion, the forward PS ratio is approximately 2.8x, which is reasonable for a commercial-stage biotech. The stock is fairly valued relative to the acquisition price but overvalued if the deal fails. The market is pricing in the acquisition premium, and any deviation from that expectation would cause a significant re-rating.
CRNX is a high-risk, high-reward stock currently trading near its acquisition price. The stock offers limited upside (7.3% to the high analyst target of $90) but significant downside risk (-34.4% to the low target of $55) if the Vertex deal fails. For investors confident the deal will close, the stock is fairly valued and may offer a small arbitrage opportunity. However, for long-term investors seeking growth, the risk of deal failure and the lack of profitability make it a speculative hold. It is not a good buy for conservative investors, but may appeal to those with a high risk tolerance and a short-term horizon until the deal closes.
CRNX is best suited for short-term investment, specifically as a merger arbitrage play until the Vertex acquisition closes (expected within 12 months). The stock's value is tied to the deal, and once closed, the upside is capped. Long-term investors would be buying Vertex shares indirectly, but the current price offers limited long-term growth potential. The stock's beta of 0.23 suggests low historical volatility, but the recent 134.6% monthly surge shows extreme short-term risk. A minimum holding period of 6-12 months is recommended, aligned with the expected deal timeline. For long-term investors, waiting for the deal to close and then evaluating Vertex as a core holding may be more appropriate.